Profound Medical vs Vivos Therapeutics
Vivos Therapeutics reported revenue of $17 million in fiscal 2025, about the same as Profound Medical's $16 million in fiscal 2025. Profound Medical's revenue grew 50.7% in its latest year, and Vivos Therapeutics' grew 16.1%. Profound Medical had an operating margin of -256.3%, against -114.0% at Vivos Therapeutics. Free cash flow was −$38 million at Profound Medical and −$18 million at Vivos Therapeutics.
Side by side
| Profound Medical | Vivos Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $16M | $17M |
| Revenue growth | 50.7% | 16.1% |
| Revenue growth a year, last 5 years | 17.1% | 5.8% |
| Gross margin | 70.8% | 60.4% |
| Operating margin | −256.3% | −114.0% |
| Net margin | −264.4% | −121.4% |
| Free cash flow | −$38M | −$18M |
| Free cash flow margin | −238.4% | −100.9% |
| Return on capital | −304.9% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 22.1% | 104.7% |
| Last close | $6.59 | $0.06 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $1.8 million, sold $0 |
| Piotroski F-score | 5 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Profound MedicalVivos Therapeutics
Operating margin
Percent of revenue
Profound MedicalVivos Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Profound MedicalVivos Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Profound Medical and Vivos Therapeutics pages.